Affiliations 

  • 1 Rheumatology Unit, Department of Medicine, Hospital Selayang, Selangor, Malaysia
  • 2 Klinik Kesihatan Sungai Pelek, Ministry of Health Malaysia, Selangor, Malaysia
  • 3 Klinik Kesihatan Sungai Buloh, Ministry of Health Malaysia, Selangor, Malaysia
  • 4 Klinik Kesihatan Kuala Selangor, Ministry of Health Malaysia, Selangor, Malaysia
  • 5 Faculty of Medicine, Universiti Teknologi MARA, Campus Sungai Buloh, Sungai Buloh, Malaysia
Oman Med J, 2023 Jul;38(4):e528.
PMID: 37736055 DOI: 10.5001/omj.2023.87

Abstract

OBJECTIVES: Gout is a treatable disease. A complication of untreated or poorly-controlled gout is tophi formation. We conducted this study to investigate the associated factors of tophaceous gout among patients who attended 20 primary care clinics in Selangor, an urbanized state in Malaysia.

METHODS: We conducted a cross-sectional study from July to October 2019 that included all patients with gout who attended the clinics. Data on clinical demographics and laboratory results were collected. Comparison between tophaceous and non-tophaceous groups was performed using descriptive analysis.

RESULTS: A total of 421 patients with gout were involved in this study, 83 (19.7%) patients had visible tophi and were categorized into the tophaceous group, while the other 338 (80.3%) patients were categorized into the non-tophaceous group. The majority of patients were male with a mean age of 57.6±12.8 years. Three factors found to be significantly associated with tophaceous gout were age at symptom onset [tophaceous (45.6±13.3 years) vs. non-tophaceous (49.7±13.9 years), p = 0.026], mean disease duration of gout [tophaceous (105.2±92.6 months) vs. non-tophaceous (77.6±88.6 months), p = 0.013], and baseline serum uric acid level [tophaceous (622.3±129.1 µmol/L) vs. non-tophaceous (582.6±102.3 µmol/L), p = 0.021].

CONCLUSIONS: Tophaceous gout is associated with longer disease duration, higher baseline serum uric acid level, and younger age at symptoms onset. Hence, early initiation of urate-lowering therapy with a treat-to-target approach is crucial to prevent tophi formation.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.